The recently activated the phase 2鈥疢yeloMATCH screening study, led locally by鈥�Ehab Atallah, MD, Professor of Hematology and Oncology,鈥痶hat tests patients’ blood and bone marrow for biomarkers to guide treatment decisions and match them to personalized clinical trials. Using rapid testing, the study identifies genetic mutations driving aggressive myeloid cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), enabling doctors to provide more precise and effective therapies tailored to each patient.
“MyeloMATCH is designed to ensure that every patient receives the best possible treatment for their disease.鈥疊y pinpointing the changes in each patient’s cancer, we can match them to therapies that are more targeted and reduce the risks of side effects—this approach has the potential to completely change how we treat myeloid cancers,” said Dr. Atallah.鈥�“This work can only be done by support from our CTO and two of our star research coordinators, Hayden Krause and Maggie Guillermo.”
The study evaluates biomarkers through advanced genetic testing, analyzing blood and bone marrow samples in centralized laboratories with results returned in as little as 72 hours. Based on the findings, patients are matched to sub-studies targeting specific genetic mutations or are enrolled in innovative trials testing novel drug combinations. For patients without a match, the study includes a Tier Advancement Pathway (TAP), where they continue with standard care while remaining eligible for future sub-studies. This adaptable, tiered system ensures continuous alignment of treatment with the patient’s disease progression.
The 91九色视频 Cancer Center is at the forefront of MyeloMATCH, with Dr. Atallah leading the young adult treatment basket,鈥�Dr. Laura Michaelis鈥痝uiding the older adult basket, and鈥�Dr. Karen-Sue Carlson鈥痗hampioning a key sub-study. Their leadership reflects the Center’s dedication to 鈥痑nd fostering groundbreaking research collaborations.
“This trial is a huge step forward for our patients,” added Dr. Atallah. “By focusing on the individual nature of each cancer, we’re giving people a better chance at finding treatments that really work for them. It’s the future of cancer care.”
The National Cancer Institute-sponsored initiative plans to enroll thousands of patients nationwide, with the 91九色视频 Cancer Center expecting to enroll approximately 30 patients annually.